4//SEC Filing
Margrave David R. 4
Accession 0001213900-20-015047
CIK 0001763950other
Filed
Jun 14, 8:00 PM ET
Accepted
Jun 15, 5:32 PM ET
Size
6.2 KB
Accession
0001213900-20-015047
Insider Transaction Report
Form 4
Margrave David R.
Chief Financial Officer
Transactions
- Award
Stock Option
2020-06-15+78,300→ 78,300 totalExercise: $15.00→ Common Stock (78,300 underlying)
Footnotes (1)
- [F1]Pursuant to the employment agreement between the Issuer and the Reporting Person as Chief Financial Officer, the Reporting Person was granted stock options to purchase 78,300 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering ("IPO") under the terms and conditions of the Issuer's Amended and Restated 2018 Equity Incentive Plan. The exercise price equals the price per share sold in the Issuer's offering. One-third of the options will vest 180 days from the closing of the Issuer's IPO (the "Grant Date"), with the remaining two-thirds of the options vesting in equal monthly increments over the period commencing the 181st day after the Grant Date and ending 30 months thereafter (or 36 months after the Grant Date). Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date.
Documents
Issuer
Lantern Pharma Inc.
CIK 0001763950
Entity typeother
Related Parties
1- filerCIK 0001813162
Filing Metadata
- Form type
- 4
- Filed
- Jun 14, 8:00 PM ET
- Accepted
- Jun 15, 5:32 PM ET
- Size
- 6.2 KB